The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
Researchers profiled cancer gene mutations, expression, protein patterns, and other features in 23 recurrent or metastatic cases of olfactory neuroblastoma.
The team hopes to commercialize the technology by producing cost-effective tests to rapidly diagnose common upper respiratory viral pathogens.
Third quarter sales of $535.0 million beat analysts' average estimate of $508 million and represented 3 percent growth on a currency-neutral basis.
Investigators used gene expression and immunological profiling to detect distinct immune responses in dengue virus-infected children with or without symptoms.
The researchers described gut microbial diversity and composition differences in metastatic melanoma patients who did or did not respond to immunotherapy.
Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.
Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.
Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.
In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.
In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.